Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Physical Activity for Reduction of Recurrence Rate After Adjuvant Chemotherapy for Localised Colorectal Carcinoma

  • feasibility of physical activity
  • increase of physical conversation
  • Quality of Life (optional)
  • vascular and metabolic effects

Studieoversikt

Status

Fullført

Detaljert beskrivelse

In this phase II pilot project the feasibility of a defined medical physical activity should be verified for increased physical conversation. The study is conducted multicentric (single group) with a study population of 30 patients. After completion of adjuvant chemotherapy the patients will participate a defined physical training, 3 times per week within a time period of 52 weeks. Planned study duration 2 years.

Studietype

Observasjonsmessig

Registrering (Faktiske)

30

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Salzburg, Østerrike, 5020
        • Paracelsus Medical University Salzburg-Oncology, Coop. Group
    • Carinthia
      • St. Veit a. d. Glan, Carinthia, Østerrike, 9330
        • Hospital BHB St. Veit/Glan, Surgery
    • Tyrol
      • Innsbruck, Tyrol, Østerrike, 6020
        • Medical University Innsbruck, Internal Medicine
      • Kufstein, Tyrol, Østerrike, 6330
        • District Hospital Kufstein
    • Upper Austria
      • Linz, Upper Austria, Østerrike, 4020
        • AKH Linz
      • Wels, Upper Austria, Østerrike, 4600
        • Klinikum Wels-Grieskirchen
    • Vorarlberg
      • Rankweil, Vorarlberg, Østerrike, 6830
        • State Hospital Rankweil

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Sannsynlighetsprøve

Studiepopulasjon

subjects with localised colorectal carcinoma

Beskrivelse

Inclusion Criteria:

  • complete resected, histologically confirmed adeno carcinoma of colon or rectal and condition after (neo-)adjuvant therapy either in (1) stage III or (2) stage II with risk factor
  • 4-16 weeks after the end of an adjuvant chemotherapy
  • ECOG 0,1
  • Age > 18 years
  • adequate liver-, nephro- and hemogram parameters
  • physical eligibility

Exclusion Criteria:

  • significant comorbidities which exclude the participation
  • evidence of local recurrence or distant metastases
  • non-compliance of subject
  • other malignancy within the last 5 years (except: skin basalioma, cervix carcinoma in situ)
  • clinically significant cardiovascular diseases
  • treatment with beta blocker without possibility of adjustment
  • left bundle-branch block
  • simultaneous chemotherapy or radiotherapy
  • pregnancy

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Kohorter og intervensjoner

Gruppe / Kohort
ingen behandling

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
feasibility of physical activity
Tidsramme: after 3 months
evaluation by frequency and duration of training interruptions or training discontinuations
after 3 months
feasibility of physical activity
Tidsramme: after 6 months
evaluation by frequency and duration of training interruptions or training discontinuations
after 6 months
feasibility of physical activity
Tidsramme: after 12 months
evaluation by frequency and duration of training interruptions or training discontinuations
after 12 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
increase of physical efficiency
Tidsramme: after 3 months
evaluation by exercise ergometry which will be compared with baseline exercise ergometry
after 3 months
increase of physical efficiency
Tidsramme: after 6 months
evaluation by exercise ergometry which will be compared with baseline exercise ergometry
after 6 months
increase of physical efficiency
Tidsramme: after 12 months
evaluation by exercise ergometry which will be compared with baseline exercise ergometry
after 12 months
Quality of Life scores
Tidsramme: study start
optional evaluation by EORTC QLQ-C30 in several trial sites
study start
Quality of Life scores
Tidsramme: after 3 months
optional evaluation by EORTC QLQ-C30 in several trial sites
after 3 months
Quality of Life scores
Tidsramme: after 6 months
optional evaluation by EORTC QLQ-C30 in several trial sites
after 6 months
Quality of Life scores
Tidsramme: after 9 months
optional evaluation by EORTC QLQ-C30 in several trial sites
after 9 months
Quality of Life scores
Tidsramme: after 12 months
optional evaluation by EORTC QLQ-C30 in several trial sites
after 12 months
vascular and metabolic effects
Tidsramme: study start
10mL blood sample (EDTA) for analyzing of vascular and metabolic effects due to a structured training program after tumour disease
study start
vascular and metabolic effects
Tidsramme: after 3 months
10mL blood sample (EDTA) for analyzing of vascular and metabolic effects due to a structured training program after tumour disease
after 3 months
vascular and metabolic effects
Tidsramme: after 12 months
10mL blood sample (EDTA) for analyzing of vascular and metabolic effects due to a structured training program after tumour disease
after 12 months
changes of cytokines and adiponectines
Tidsramme: study start
10mL blood sample (EDTA) for analyzing of changes of cytokines and adiponectines due to a structured training program after tumour disease
study start
changes of cytokines and adiponectines
Tidsramme: after 3 months
10mL blood sample (EDTA) for analyzing of changes of cytokines and adiponectines due to a structured training program after tumour disease
after 3 months
changes of cytokines and adiponectines
Tidsramme: after 12 months
10mL blood sample (EDTA) for analyzing of changes of cytokines and adiponectines due to a structured training program after tumour disease
after 12 months
gen- and metabolic signs
Tidsramme: study start
10mL blood sample (EDTA) for analyzing of gen- and metabolic signs due to a structured training program after tumour disease
study start
gen- and metabolic signs
Tidsramme: after 3 months
10mL blood sample (EDTA) for analyzing of gen- and metabolic signs due to a structured training program after tumour disease
after 3 months
gen- and metabolic signs
Tidsramme: after 12 months
10mL blood sample (EDTA) for analyzing of gen- and metabolic signs due to a structured training program after tumour disease
after 12 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studiestol: Michael Fridrik, MD, Austrian Breast & Colorectal Cancer Study Group
  • Studiestol: Alfred Fridrik, MD, Austrian Breast & Colorectal Cancer Study Group

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. oktober 2010

Primær fullføring (Faktiske)

1. april 2013

Studiet fullført (Faktiske)

1. april 2013

Datoer for studieregistrering

Først innsendt

23. september 2010

Først innsendt som oppfylte QC-kriteriene

27. september 2010

Først lagt ut (Anslag)

28. september 2010

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

9. juni 2022

Siste oppdatering sendt inn som oppfylte QC-kriteriene

7. juni 2022

Sist bekreftet

1. juni 2022

Mer informasjon

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere